Deep Learning Market Size
The global deep learning market, valued at USD 6.4 billion in 2025, is projected to reach USD 8.2 billion in 2026 and USD 34.5 billion by 2035, with a 17.3% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Deep Learning Market Trends and Key Takeaways
Market Size & Trends
- With regards to therapeutic area, the oncological disorders segment dominates the global market.
- In terms of geographical regions, North America captures the majority of the market share. Notably, Asia-Pacific is anticipated to grow at a faster pace in the near future.
Key Market Statistics
- Market Size in 2026: $8.2 Billion
- Estimated Market Size in 2035: $34.5 Billion
- CAGR (2026-2035): 17.3%
- North America: Largest market in 2026
- Asia-Pacific: Fastest growing region
Deep Learning Market Overview
Since the mid-twentieth century, computing devices have continually been explored for applications beyond mere calculations, to emerge as machines that possess intelligence. These targeted efforts have led to the emergence of artificial intelligence, the next-generation simulator that employs programmed machines possessing the ability to comprehend data and execute the instructed tasks. The progress of artificial intelligence can be attributed to machine learning, a field of study that imparts computers with the ability to think without being explicitly programmed.
Deep learning is a complex machine learning algorithm that uses a neural network of interconnected nodes / neurons in a multi-layered structure, thereby enabling the interpretation of large volumes of unstructured data to generate valuable insights, making it a promising approach for big data analysis. Owing to the distinct characteristic of deep learning algorithm to imitate the human brain, it is currently being deployed in the life sciences industry, primarily for the purposes of drug discovery and diagnostics. Considering the challenges associated with drug discovery and drug development, such as the high attrition rate and increased financial burden, deep learning has been found to improve the overall drug discovery productivity.
Recent advancements in the deep learning technology have demonstrated its potential in other healthcare-associated segments, such as AI in medical imaging, molecular profiling, virtual screening and data analysis. Driven by the ongoing pace of innovation and the profound impact of this field of computational medicine, deep learning is anticipated to witness substantial growth in the foreseen future.
Recent Developments
- In March 2026, OpenAI closed a USD 122 billion funding round at a post-money valuation of USD 852 billion to accelerate foundational AI development including advanced deep learning models for generative AI and broad industry applications.
- In March 2026, Eli Lilly and Insilico Medicine announced a USD 2.75 billion collaboration, expanding their prior AI software licensing to pursue novel oral therapeutics using Insilico's deep learning AI engine for drug discovery and development across multiple targets.
- In February 2026, Takeda Pharmaceuticals entered into a collaboration worth up to USD 1.7 billion with Iambic Therapeutics, accessing AI-driven drug discovery platforms including generative chemistry for novel chemical modalities targeting difficult proteins, with upfront, research, and milestone payments.
- In January 2026, NVIDIA launched Rubin platform featuring six new chips for extreme AI supercomputing, slashing training time and inference costs for deep learning workloads globally.
- In June 2025, AstraZeneca collaborated with CSPC Pharmaceuticals, leveraging CSPC’s AI and deep learning-driven drug discovery platform for small-molecule candidates in immunology and chronic diseases, with USD 110 million upfront, up to USD 5.2 billion in milestones, and royalties..
Deep Learning Market Trends
- Over 240 clinical studies are being conducted to evaluate deep learning in diagnostics: Several industry and academic players are actively conducting clinical studies for the evaluation of applying deep learning algorithms for diagnostic purposes, highlighting the continuous pace of innovation in this field.
- Emergence of Startups: The field is evolving continuously, as a number of start-ups have emerged with the aim of developing deep learning technologies / software. In the past seven years, over 60 companies providing deep learning-based solutions have been established.
- Increased market activity to support the use of deep learning in drug discovery process: In February 2024, VantAI entered into an agreement with Bristol Myers Squibb in order to integrate its deep learning capabilities with latter’s targeted protein degradation expertise for the discovery, design and development of molecular glues and novel small molecule therapeutics. In December 2023, Apple Tree Partners announced the launch of its portfolio company Deep Apple Therapeutics with a USD 52 million series A funding round with an aim of accelerating drug discovery using deep learning models. Deep Apple Therapeutics’ discovery engine is believed to enable dramatic reduction in the drug discovery timeline, to a period of 12 months, starting from target identification to lead optimization, across a myriad of disease indications.
Industry Experts
The deep learning market report features detailed transcripts of interviews (in reverse chronological order) held with the following key industry stakeholders:
- Chief Executive Officer, Small Company, India
- Founder and Chief Executive Officer, Small Company, India
- Former Vice President of Product and Software Development, Mid-sized Company, USA
- Head of Strategy and Marketing, Mid-sized Company, USA
- Chief Technical Officer, Small Company, India and Chief Operating Officer, Small Company, India
- Former Research Scientist, Small Company, Sweden
- Chief Executive Officer, Small Company, South Korea
- Chief Executive Officer, Mid-sized company, USA and Commercial Strategy and Operations Lead, Mid-sized company, USA
Deep Learning Market Share Insights
Market Analysis: Deep Learning in Diagnostics Holds the Largest Market Share
- As of 2026, the market size for application of deep learning in diagnostics is estimated to be $5.4 billion. This is because of increased efficiency and precision of applying deep learning-powered diagnostic solutions.
- Further, the deep learning in drug discovery market is anticipated to grow at a relatively higher CAGR of 21.1% during the forecast period with several pharmaceutical companies actively collaborating with solution providers for drug design and development.
Market Share by Therapeutic Area
- Global market for deep learning in drug discovery and diagnostics is segmented across oncological disorders, infectious diseases, neurological disorders, immunological disorders, endocrine disorders, cardiovascular disorders, respiratory disorders, eye disorders, musculoskeletal disorders, inflammatory disorders and other disorders.
- Oncological disorders hold the largest deep learning market share currently and this trend is unlikely to change in the near future.
Market Share by Geographical Regions
- North America is the leading region, holding 45% share of the market in the current year.
Key Market Insights
Need for Deep Learning in Drug Discovery and Diagnostics
The use of deep learning in drug discovery has the potential to reduce capital requirements and the failure-to-success ratio, as algorithms are better equipped to analyze large datasets. Similarly, in diagnostics market, deep learning technology can be used to assist medical professionals in medical imaging and interpretation. This enables quick and efficient diagnosis of disease indications at an early stage.
Current Market Landscape: More than 200 Players are Contributing to Development of this Field
The deep learning market for drug discovery and diagnostics market landscape features more than 200 companies are focused on providing deep learning services and technologies for drug discovery and diagnostic purposes. The primary focus areas of these companies include big data analysis, medical imaging, medical diagnosis and molecular data analysis.
The deep learning in diagnostics segment features the presence of 139 players, which is dominated by the presence of small players (49%) owing to the technological advances in this field. Further, these players are engaged in offering services across a wide range of therapeutic areas, with the primary focus on oncological disorders.
It is worth highlighting that deep learning-powered diagnostic service providers offer various diagnostic solutions, such as structured analysis reports, image interpretation and biomarker identification solutions, with input data from several compatible devices. In this context, image processing services emerged as the most prominent type of service offered by the companies (83%) engaged in the deep learning in diagnostics domain.
Deep Learning in Drug Discovery Market Size
Deep learning market for drug discovery is estimated to be $1.1 billion in the current year. In terms of therapeutic area, oncology is expected to capture the largest market share. This is due to the fact that deep learning allows the optimized categorization of histopathological images by comparing it with a vast dataset of such images, that enables enhanced diagnosis, prognosis and targeted treatment selection for oncological disorders.
Lately, the industry has also witnessed the development of advanced deep learning technologies and software. These technologies possess the ability to obviate the concerns associated with the conventional drug discovery process and aid in the reduction of financial burden associated with drug discovery. The application of deep learning focusing on drug discovery is anticipated to grow at a CAGR of 21.1% in the forecast period till 2035.
Deep Learning in Diagnostics Market Size
Deep learning market for diagnostics, specifically for musculoskeletal and eye disorders is estimated to be $3.9 billion in 2035. The adoption of deep learning technologies to assist medical diagnosis, primarily through medical imaging, has increased in the recent past. In April 2025, Damo Academy (a part of Alibaba group Holding) received FDA approval for Damo Panda, a deep learning based pancreatic cancer detection tool. The model is trained on abdominal non-contract CT images of 3,208 pancreatic cancer patients. AI is being employed for disease diagnostics in animals as well. Zoetis, an animal health company, announced the addition of a new feature, AI Masses, to its Vetscan Imagyst analyzer in June 2025. Their Vetscan Imagyst system is an advanced deep learning trained model for cancer detection. The global deep learning market focusing on diagnostics is anticipated to grow at a CAGR of 17.3% till 2035.
By 2035, the deep learning in diagnostics market in North America is expected to capture the majority share. In terms of therapeutic areas, the deep learning in diagnostics market for musculoskeletal and eye disorders is anticipated to grow at a relatively faster pace by 2035, growing at a CAGR of 23% and 21%, respectively.
Key Market Drivers: Analysis of Big Data with the Help of Deep Learning
In the last decade, the healthcare industry has witnessed an inclination towards the adoption of information services and digital analytical solutions. This can be attributed to the fact that companies have recently shifted towards high-resolution medical images and electronic health and medical records, generating large and complex data, referred to as big data. In order to analyze such large datasets, efficient tools and technology, such as deep learning, are required. Thus, the emergence of big data is anticipated to be a primary driver of the adoption of deep learning and artificial intelligence in the healthcare industry.
Top Deep Learning Companies (Drug Discovery)
Examples of top deep learning companies for drug discovery (which have also been captured in this report) include Atomwise, Benevolent.ai, Cloud Pharmaceuticals, Deargen, Deep Cure, Exscientia, GNS Healthcare, Insilico Medicine, Isomorphic Labs, Juvena Therapeutics, Merative, Optibrium,x and Valence Discovery. This deep learning market report includes and easily searchable excel database for all the companies offering deep learning for drug discovery.
Top Deep Learning Companies (Diagnostics)
Examples of top deep learning companies for diagnostics (which have also been captured in this report) include Avalon AI, Behold.ai, Blueberry Diagnostics, Deep Longevity, Esaote, Enlitic, Flatiron Health, H2O.ai, Huawei, InMed Prognostics, Kheiron Medical, Mediwhale, Nference, and Visiopharm. This market report includes and easily searchable excel database for all the companies offering deep learning for diagnostics.
Deep Learning Market Segmentation Insights
| Report Attributes |
Details |
| Historical Trends |
Since 2023 |
| Base Year |
2025 |
| Forecasted Estimates |
Till 2035 |
| CAGR (Till 2035) |
17.3% |
| Market Size (2026) |
$8.2 Billion |
| Market Size (2035) |
$34.5 Billion |
| Therapeutic Areas |
- Oncological Disorders
- Infectious Diseases
- Neurological Disorders
- Immunological Disorders
- Endocrine Disorders
- Cardiovascular Disorders
- Respiratory Disorders
- Eye Disorders
- Musculoskeletal Disorders
- Inflammatory Disorders
- Other Disorders
|
| Key Geographical Regions |
- North America
- Europe
- Asia Pacific
- Rest of the World
|
| Key Players |
- Aegicare
- Aiforia Technologies
- Ardigen
- Berg
- Google
- Huawei
- Merative
- Nference
- Nvidia
- Owkin
- Phenomic AI
- Pixel AI
|
| Customization Scope |
15% Free Customization Option (equivalent to 5 analyst’s working days) |
PowerPoint Presentation
(Complimentary) |
Available |
Excel Data Packs
(Complimentary) |
- Market Landscape Analysis (Drug Discovery)
- Market Landscape Analysis (Diagnostics)
- Clinical Trial Analysis
- Funding Analysis
- Start-up Health Indexing
- Company Valuation Analysis
- Market Sizing and Opportunity Analysis (Drug Discovery)
- Market Sizing and Opportunity Analysis (Diagnostics)
|
Frequently Asked Questions
Question 1: What is deep learning?
Answer: Deep learning is a machine learning technique that allows computers to process and analyze data simulating the human brain, in order to model and solve complex patterns and problems to produce accurate insights.
Question 2: How big is deep learning market for drug discovery and diagnostics?
Answer: The current deep learning market size (for drug discovery and diagnostics) is estimated to be $8.2 billion.
Question 3: Which region has the highest growth rate in the deep learning in diagnostics market?
Answer: The deep learning for diagnostics market in North America is likely to grow at the highest CAGR, during the period till 2035.
Question 4: What is the growth rate (CAGR) of the deep learning in drug discovery and diagnostics market?
Answer: Deep learning market is anticipated to grow at a CAGR of 17.3% in the forecast period, till 2035.
Question 5: How many companies offer deep learning technologies / services for drug discovery and diagnostics?
Answer: Presently, more than 200 players are engaged in the deep learning industry, offering technologies / services, specifically for drug discovery and diagnostics purposes.
Question 6: How much money has been invested in the field of deep learning in drug discovery and diagnostics?
Answer: Since 2019, more than $15 billion has been invested in deep learning in drug discovery and diagnostics industry across multiple funding instances.
Question 7: How much cost does deep learning technologies save in diagnostics?
Answer: Considering the vast potential of artificial intelligence, deep learning technologies are believed to save around 45% of the overall drug diagnostic costs.
Question 8: How many clinical trials, based on deep learning technologies, are being conducted?
Answer: Currently, more than 420 clinical trials are being conducted to evaluate the potential of deep learning for diagnostic purposes.
